Optimi Health Corp operates in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector. The company has one reportable operating segment being that of the farming, processing, and distribution of raw mushroom biomass. It also intends to cultivate, extract, process, and distribute strains of fungi products at its facilities located in Princeton, British Columbia.
Last trade$2.07
Day change-$0.08 (-3.72%)
Day range$1.97 – $2.20
Volume15,939
Market cap$12M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for OPTH.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for OPTH.
Recent news
Company coverage with links to the original publishers.
Optimi Health Corp., a commercial-stage pharmaceutical manufacturer of psychedelic drug products, announced its participation in the ThinkEquity Conference on October 15, 2026, in New York City. Management will present a corporate overview and meet with investors. The company is a Health Canada-licensed manufacturer producing GMP-grade MDMA and psilocybin products for mental health therapies.
Optimi Health completed its third commercial shipment of 5mg psilocybin capsules to Australia, exporting 1,000 capsules for treatment-resistant depression patients. The company reports no serious adverse events since the September 2025 launch and notes expanding reimbursement coverage from both private and public insurers in Australia.
SRx Health Solutions has completed its acquisition of EMJ Crypto Technologies (EMJX) and rebranded as SRX Global Inc. The company is launching an AI-driven platform strategy focused on capital allocation into high-conviction operating companies and assets. The merged entity will be led by Kent Cunningham as CEO and Eric Jackson as President and Head of Asset Management, with initial investments in companies including Astro Capital, Opendoor Technologies, Uber Technologies, and Optimi Health Corp.
Optimi Health Corp. announced the completion of two standardized microdose psilocybin finished drug products at 1mg and 2mg dosages for clinical research organizations. The products offer consistent, validated doses derived from naturally sourced psilocybin, extending Optimi's existing 5mg formulation currently prescribed for treatment-resistant depression in Australia. All production is conducted in-house at Optimi's GMP-compliant facility in British Columbia, Canada.
Optimi Health has completed a GMP production run of its 5mg psilocybin finished drug product for commercial use in Australia to treat treatment-resistant depression. The company manufactures the entire product in-house at its Health Canada-licensed facility, from biomass cultivation through final packaging. Additional product from the run will support clinical trials in the United States and Europe.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.